Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 14, 2014

View Archived Issues

Academic team divulges novel FimH inhibitors

VolitionRx enters into agreement with University of Oxford for endometriosis diagnostic

Radboud University Medical Center wins NuGEN award for sarcoma genomics research

Medgenics and CHOP collaborate on pediatric rare and orphan genetic diseases

Enterome and AbbVie establish microbiome collaboration in Crohn's disease

Glionova Therapeutics raises financing for clinical development of glioblastoma candidate

BioCardia to conduct phase III trial of autologous bone marrow cell therapy for heart failure

GenomeDx and Mayo Clinic collaborate on expanded use of prostate cancer test

FDA approves supplemental NDAs for Invega Sustenna

First-in-human results for GSK-2878175 in healthy volunteers and patients with HCV

Advaxis submits IND for phase I/II study of ADXS-HPV and MEDI-4736 for HPV-related cancers

Phase II study of masitinib in hepatocellular cancer recommended to continue by DSMB

Safety and pharmacokinetic results for first-in-class HBV core inhibitor NVR-3-778

Suppression of Bcl-xL in hepatocellular carcinoma cells by TPU-0014

Presage expands cancer research agreement with Takeda

Arrien Pharmaceuticals patent details novel dual ITK/JAK3 inhibitors

Innocrin Pharmaceuticals to participate in phase II trial of VT-464 in prostate cancer

New lead candidates for broad-spectrum antimalarial drugs presented

University of Queensland developing new vaccine technology for polio

Japanese researchers describes anti-NLRR-1 MAbs

Merck & Co. presents preliminary phase I results for recombinant dengue vaccine

Janssen licenses Geron's imetelstat

Quatsomes EGF formulation developed to treat diabetic foot ulcers

Clinical trials of favipiravir and brincidofovir planned in Ebola virus outbreak region

Mitsubishi Tanabe seeks Japanese approval of Radicut for ALS

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...